Brokers Offer Predictions for TSE:ONC FY2024 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at Leede Financial issued their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued on Wednesday, November 13th. Leede Financial analyst D. Loe expects that the company will post earnings of ($0.34) per share for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.05) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Stock Up 0.7 %

ONC opened at C$1.39 on Monday. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. Oncolytics Biotech has a fifty-two week low of C$1.15 and a fifty-two week high of C$2.32. The firm’s fifty day moving average is C$1.50 and its 200 day moving average is C$1.45. The stock has a market cap of C$106.84 million, a price-to-earnings ratio of -3.63 and a beta of 1.35.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.